Table 2.
One-year risk and hazard ratio for incident diabetes by CMDS score group and treatment arm
| n | Diabetes* (number of cases) | One-year risk,† % (95% CI) | Adjusted hazard ratio‡ (95% CI) | |
|---|---|---|---|---|
| 0–29/Treatment§ | 558 | 3 | 0.67 (0–1.44) | 0.05 (0.02–0.16) |
| 30–59/Treatment | 644 | 13 | 2.37 (1.08–3.64) | 0.19 (0.10–0.36) |
| 60+/Treatment | 526 | 33 | 6.29 (4.11–8.43) | 0.59 (0.36–0.95) |
| 0–29/Placebo | 495 | 5 | 1.51 (0.16–2.83) | 0.10 (0.04–0.27) |
| 30–59/Placebo | 450 | 19 | 4.67 (2.43–6.86) | 0.43 (0.25–0.76) |
| 60+/Placebo | 367 | 34 | 10.43 (6.88–13.85) | Reference¶ |
*Number of cases of new-onset diabetes.
†One-year (56-week) risk for incident diabetes was calculated from Kaplan-Meier survival curves.
‡Adjusted for age, sex, and race/ethnicity.
§0–29/Treatment: participants who had a CMDS score in the range of 0–29 and received weight-loss medication (7.5 mg phentermine/46 mg topiramate or 15 mg phentermine/92 mg topiramate).
¶When the 30–59/Placebo group served as the reference group, hazard ratio for incident diabetes in the 30–59/Treatment group was 0.44 (95% CI 0.22–0.89). When the 0–29/Placebo group served as the reference group, hazard ratio for incident diabetes in the 0–29/Treatment group was 0.48 (95% CI 0.12–2.01).